SEC Tracker
Get the app
VNRX · XBRL financial data

VolitionRx financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (VNRX's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025†Mar 31, 2026Jun 30, 2026
Revenue165244*172396475192*246407627447*985399
Research and development4,6514,544*4,6303,7163,4742,587*2,6072,7202,2862,468*2,8521,801
General and administrative2,6002,542*2,2542,2841,8162,134*2,2432,9412,4841,796*2,6302,205
Total operating expenses8,8188,985*8,5567,3866,3435,973*5,7686,7045,7285,265*6,3344,555
Operating income (loss)(8,653)(8,741)*(8,385)(6,990)(5,869)(5,781)*(5,522)(6,298)(5,101)(4,818)*(5,349)(4,156)
Interest expense——————97123——126740
Other income (expense)200(59)*(88)(70)0(76)*45(16)(309)(1,484)*(1,355)(3,159)
Net income (loss)(8,453)(8,800)*(8,472)(7,060)(5,869)(6,084)*(5,424)(6,284)(5,378)(6,271)*(6,665)(7,326)
Earnings per share, diluted USD per share——(0.10)(0.08)(0.07)(0.07)*(0.06)(0.06)(0.05)(0.05)*(0.97)(0.85)
Weighted average shares, diluted thousands of shares——81,95782,66987,88693,521*96,536102,654108,213119,656*6,8839,155
  • † Share count changed about 1/19 in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Balance sheet

CSV

Fiscal quarters (VNRX's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025†Mar 31, 2026Jun 30, 2026
Cash and cash equivalents10,80920,73011,7725,9995,4143,2642,6002,3002001,1173,1032,800
Accounts receivable34243134166313111188190309318252277
Total current assets12,19721,85413,4707,3456,8014,0573,2943,2631,3322,0614,5164,093
Property and equipment, net5,3055,5235,1814,8784,9084,4294,3484,5004,2434,0283,7713,564
Right-of-use asset490550569512636600561635572496430339
Total assets18,04127,95019,43513,06812,6809,4008,5208,7056,4496,9019,0368,301
Accounts payable3,0603,2113,5283,3482,4852,7663,0122,3513,1142,9193,7193,565
Accrued liabilities2,8683,9293,3053,2283,4803,4773,6994,3894,5854,2123,8702,670
Current portion of long-term debt1,2581,2071,1501,0439658608621,0179148919401,070
Total current liabilities17,65431,83731,49230,97630,2797,7918,2739,24111,42212,23113,56713,493
Long-term debt2,0863,6253,3733,8653,8383,9535,5325,7715,5665,8186,3525,982
Lease liability, non-current324378396351448411369417351277209157
Total liabilities20,89236,66336,05535,96635,32135,50737,54741,80342,39842,49442,39641,840
Accumulated deficit(193,878)(202,577)(210,944)(217,929)(223,751)(229,544)(234,968)(241,252)(246,631)(252,901)(259,566)(267,352)
Total stockholders' equity(2,043)(7,802)(15,605)(21,808)(21,504)(24,908)(27,774)(31,815)(34,635)(34,246)(31,975)(32,165)
Total liabilities and equity18,04127,95019,43513,06812,6809,4008,5208,7056,4496,9019,0368,301
Common shares outstanding (cover page) thousands of shares78,68682,06882,81592,10192,66596,544103,023107,595122,802158,4818,33013,649
  • † Share count changed about 1/19 in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Cash flows

CSV

Fiscal quarters (VNRX's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025†Mar 31, 2026Jun 30, 2026
Net income (loss)(8,453)(8,800)*(8,472)(7,060)(5,869)(6,084)*(5,424)(6,284)(5,378)(6,271)*(6,665)(7,326)
Stock-based compensation538466*411208324326*451812*609*(133)*225238*
Net cash from operating activities(8,418)*6,448*(8,342)(6,732)*(5,387)*(5,432)*(4,298)(6,263)*(3,631)*(5,492)*(5,280)(5,160)*
Purchases of property and equipment273*309*2939*137*73*277*0*11*92*
Net cash from investing activities(273)*(309)*(79)(160)*(137)*(198)*(2)(77)*0*(11)*(9)(2)*
Proceeds from issuing common stock(13)*2,519*16589*5,960*2,027*2,38563*2,007*6,716*5,1745,435*
Share repurchases0*0*00*0*0*——————
Proceeds from long-term debt0*1,638*0754*0*614*1,5700*0*410*9630*
Repayments of long-term debt204*301*210321*301*256*252160*285*180*246180*
Net cash from financing activities(275)*3,770*(209)973*5,603*2,290*3,6675,670*1,600*6,156*7,6164,979*
Net change in cash(8,935)*9,921*(8,958)(5,773)*(585)*(2,150)*(664)(344)*(2,057)*918*1,986(312)*
  • † Share count changed about 1/19 in the period ending 2026-03-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Compare with peers

SIC 2835 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2835 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Volitionrx2,800399(5,160)*13.6M0.5 quarters 10-QJun 30, 2026
Gyre Therapeutics43,28729,105(16,728)*111.5M3.4 quarters 10-QJun 30, 2026
Oncolytics Biotech4,115not reported(8,138)*127.5M0.5 quarters 10-QJun 30, 2026
Seres Therapeutics15,594736(22,394)*9.9M0.7 quarters 10-QJun 30, 2026
Macrogenics113,90732,832(40,748)*63.7M2.8 quarters 10-QJun 30, 2026
Inovio Pharmaceuticals31,5260(18,047)*103.4M2.0 quarters 10-QJun 30, 2026
XBiotech109,528not reported(4,515)*30.5M24.3 quarters 10-QJun 30, 2026
Oramed Pharmaceuticals15,245not reported(200)*41.6M80.5 quarters 10-QJun 30, 2026
Corbus Pharmaceuticals Holdings23,370not reported(29,626)*19.3M4.0 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.